Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling
Authorized Users Only
2011
Authors
Antić, Darko
Mihaljević, Biljana

Čokić, Vladan

Dencic-Fekete, Marija
Karan-Đurašević, Teodora
Pavlović, Sonja
Milić, Nataša
Elezović, Ivo
Article (Published version)

Metadata
Show full item recordAbstract
We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p lt 0.0001).
Keywords:
Lymphoma and Hodgkin disease / molecular genetics / prognosticationSource:
Leukemia & Lymphoma, 2011, 52, 7, 1394-1397Publisher:
- Taylor & Francis Ltd, Abingdon
DOI: 10.3109/10428194.2011.578311
ISSN: 1042-8194
PubMed: 21699385
WoS: 000291992400036
Scopus: 2-s2.0-79959613190
Collections
Institution/Community
Institut za medicinska istraživanjaTY - JOUR AU - Antić, Darko AU - Mihaljević, Biljana AU - Čokić, Vladan AU - Dencic-Fekete, Marija AU - Karan-Đurašević, Teodora AU - Pavlović, Sonja AU - Milić, Nataša AU - Elezović, Ivo PY - 2011 UR - http://rimi.imi.bg.ac.rs/handle/123456789/336 AB - We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p lt 0.0001). PB - Taylor & Francis Ltd, Abingdon T2 - Leukemia & Lymphoma T1 - Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling EP - 1397 IS - 7 SP - 1394 VL - 52 DO - 10.3109/10428194.2011.578311 UR - conv_2524 ER -
@article{ author = "Antić, Darko and Mihaljević, Biljana and Čokić, Vladan and Dencic-Fekete, Marija and Karan-Đurašević, Teodora and Pavlović, Sonja and Milić, Nataša and Elezović, Ivo", year = "2011", abstract = "We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p lt 0.0001).", publisher = "Taylor & Francis Ltd, Abingdon", journal = "Leukemia & Lymphoma", title = "Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling", pages = "1397-1394", number = "7", volume = "52", doi = "10.3109/10428194.2011.578311", url = "conv_2524" }
Antić, D., Mihaljević, B., Čokić, V., Dencic-Fekete, M., Karan-Đurašević, T., Pavlović, S., Milić, N.,& Elezović, I.. (2011). Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. in Leukemia & Lymphoma Taylor & Francis Ltd, Abingdon., 52(7), 1394-1397. https://doi.org/10.3109/10428194.2011.578311 conv_2524
Antić D, Mihaljević B, Čokić V, Dencic-Fekete M, Karan-Đurašević T, Pavlović S, Milić N, Elezović I. Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. in Leukemia & Lymphoma. 2011;52(7):1394-1397. doi:10.3109/10428194.2011.578311 conv_2524 .
Antić, Darko, Mihaljević, Biljana, Čokić, Vladan, Dencic-Fekete, Marija, Karan-Đurašević, Teodora, Pavlović, Sonja, Milić, Nataša, Elezović, Ivo, "Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling" in Leukemia & Lymphoma, 52, no. 7 (2011):1394-1397, https://doi.org/10.3109/10428194.2011.578311 ., conv_2524 .